Proprietary Pipeline

Advancing a focused proprietary and partnered pipeline

A focused oncology lead asset, complemented by partnered infectious disease programmes and platform validation.

ExpreS2ion’s pipeline is led by ES2B-C001, an active immunotherapy candidate targeting HER2-expressing cancers, initially in breast cancer. The programme is currently in Phase I clinical development.

The broader pipeline includes partnered infectious disease programmes in malaria, influenza, and Nipah virus, developed with leading academic and consortium partners. These programmes provide additional validation of the ExpreS2 platform across different protein targets and disease areas.